Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469338 · ClinicalTrials.gov registry record · Phase 2
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01469338 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 9 participants.
The verdict
NCT01469338, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer
Interventions
- DRUG prednisone
- OTHER questionnaire administration
- DRUG octreotide pamoate
- DRUG octreotide acetate
- DRUG cabazitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01469338
The ClinicalTrials.gov registry entry for NCT01469338 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT01469338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01469338 about?
NCT01469338 is a clinical study titled "Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel". This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiv...
What is the current status of trial NCT01469338?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01469338?
The interventions under investigation include: prednisone (DRUG), questionnaire administration (OTHER), octreotide pamoate (DRUG), octreotide acetate (DRUG), cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT01469338?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.